Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Ramzi M. Mohammad

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8332-5246; OpenAlex author ID A5101474379; NIH RePORTER profile ID 1968485. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 7)
Trials
0
Grants
3
Labs led
1
Collaborators
32
Papers, trials and grants by year

2011: 3 papers, 1 grant · 2012: none · 2013: 1 paper, 1 grant · 2014: 3 papers · 2015: none · 2016: 1 paper, 1 grant · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 22

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  2. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  3. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  4. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. Co-author DOI 10.1016/j.canlet.2024.217275↗
  5. Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia. First author DOI 10.1152/ajpcell.00424.2022↗
  6. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Co-author DOI 10.3390/cancers13112777↗
  7. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Last author DOI 10.3390/cancers13164161↗
  8. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-1728↗
  9. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Co-author DOI 10.3390/cancers12030750↗
  10. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarc… Co-author DOI 10.1080/21541248.2017.1329694↗
  11. DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcin… Last author DOI 10.3390/cancers11081101↗
  12. Nuclear Export Inhibition for Pancreatic Cancer Therapy. Last author DOI 10.3390/cancers10050138↗
  13. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-16-0205↗
  14. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Last author DOI 10.18632/oncotarget.19285↗
  15. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm5060059↗
  16. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Co-author DOI 10.1089/scd.2013.0551↗
  17. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Co-author DOI 10.1158/1535-7163.mct-12-0767↗
  18. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Last author DOI 10.18632/oncotarget.1813↗
  19. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Last author DOI 10.1053/j.gastro.2012.10.036↗
  20. Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Co-author DOI 10.2217/epi.11.97↗
  21. Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy. Last author DOI 10.3390/cancers3021527↗
  22. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Co-author PMID 21904657↗

Grants 3

  1. Targeting PAK4 for Overcoming Drug Resistance in Pancreatic Cancer R21CA188818↗
  2. Development of Small Molecule Crm-1 Inhibitor for Pancreatic Cancer Therapy R21CA169848↗
  3. Specific Targets for Pancreatic Cancer Therapy R01CA109389↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asfar Sohail Azmi · 22 shared papers, 1 shared grant, 2011–2026 · strength 2.50
  2. Philip A. Philip · 14 shared papers, 2011–2025 · strength 1.54
  3. Amro Aboukameel · 14 shared papers, 2013–2026 · strength 1.41
  4. Md. Hafiz Uddin · 6 shared papers, 2021–2026 · strength 1.07
  5. Husain Yar Khan · 6 shared papers, 2020–2026 · strength 0.91
  6. Irfana Muqbil · 8 shared papers, 2016–2022 · strength 0.85
  7. Sahar F. Bannoura · 4 shared papers, 2024–2026 · strength 0.72
  8. Boris Pasche · 4 shared papers, 2024–2026 · strength 0.72
  9. Muhammad Wasif Saif · 4 shared papers, 2024–2026 · strength 0.72
  10. Bassel F. El‐Rayes · 4 shared papers, 2024–2026 · strength 0.72
  11. Bin Bao · 7 shared papers, 2011–2026 · strength 0.69
  12. Eliza Wright Beal · 3 shared papers, 2024–2026 · strength 0.54
  13. Yiwei Li · 5 shared papers, 2014–2021 · strength 0.49
  14. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
  15. Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
  16. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
  17. Steve H. Kim · 3 shared papers, 2020–2025 · strength 0.36
  18. Kay‐Uwe Wagner · 2 shared papers, 2021–2024 · strength 0.32
  19. Anteneh A. Tesfaye · 2 shared papers, 2020 · strength 0.19
  20. Mandana Kamgar · 2 shared papers, 2020 · strength 0.19
  21. Maria Diab · 2 shared papers, 2016–2020 · strength 0.17
  22. Fazlul H. Sarkar · 4 shared papers, 2011–2014 · strength 0.14
  23. Rachel E. Sexton · 1 shared paper, 2020 · strength 0.09
  24. Amit Mahipal · 1 shared paper, 2020 · strength 0.09
  25. Shadan S. Ali · 2 shared papers, 2011–2014 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.